董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Ferrari | 男 | Executive Chairman of the Board and Independent Director | 72 | 24.50万美元 | 30.77 | 2026-03-12 |
| Branislav Vajdic | 男 | Director and President | 72 | 94.60万美元 | 195.37 | 2026-03-12 |
| Willem Elfrink | 男 | Independent Director | 73 | 17.55万美元 | 53.48 | 2026-03-12 |
| George A. de Urioste | 男 | Independent Director | 70 | 17.55万美元 | 5.69 | 2026-03-12 |
| Mark Strome | 男 | Independent Director | 69 | 15.54万美元 | 299.35 | 2026-03-12 |
| Kenneth Nelson | 男 | Independent Director | 50 | 18.00万美元 | 16.95 | 2026-03-12 |
| Robert P. Eno | 男 | Chief Executive Officer and Director | 58 | 103.63万美元 | 48.04 | 2026-03-12 |
| Michael R. Jaff | 男 | Independent Director | 67 | 13.50万美元 | 7.93 | 2026-03-12 |
| Marga Ortigas Wedekind | 女 | Independent Director | 64 | 16.21万美元 | 17.92 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Ferrari | 男 | Executive Chairman of the Board and Independent Director | 72 | 24.50万美元 | 30.77 | 2026-03-12 |
| Branislav Vajdic | 男 | Director and President | 72 | 94.60万美元 | 195.37 | 2026-03-12 |
| Robert P. Eno | 男 | Chief Executive Officer and Director | 58 | 103.63万美元 | 48.04 | 2026-03-12 |
| Timothy Cruickshank | 男 | Chief Financial Officer | -- | 72.95万美元 | 18.26 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Richard Ferrari
-
Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida. - Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
- Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida.
- Branislav Vajdic
-
Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
Branislav Vajdic founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held vario senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numero patents and publications in the fields of cardiovascular devices as ll as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota. - Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
- Branislav Vajdic founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held vario senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numero patents and publications in the fields of cardiovascular devices as ll as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.
- Willem Elfrink
-
自我们成立以来，Willem Elfrink一直担任董事会主席，并于2021年6月辞去该职位，但仍是董事会成员。Elfrink先生在将新技术引入市场方面拥有超过40年的经验。Elfrink先生通过董事会参与，战略营销，治理和资本结构积极为投资组合公司做出贡献。Elfrink先生也是WPE Ventures Digitized Solutions（一家安全和数字化解决方案投资公司）的创始人兼总裁。Elfrink先生于1997年加入Cisco，并于2000年至2006年和2007年至2015年分别担任Cisco的行业解决方案执行副总裁和首席全球化官，在此Elfrink先生为公司的关键战略和运营决策做出了贡献。他被广泛认为是思科的常驻企业企业家，他的全球章程是确定重要的技术机会。Elfrink还领导了一个名为物联网世界论坛IOTWF的行业倡议。在加入Cisco之前，Elfrink先生在Olivetti，Xerox，HP，Digital Equipment Corporation和Philips担任管理和高级管理职位。Elfrink先生在荷兰鹿特丹的理工学院获得了工程学士学位。
Willem Elfrink was Chairman of the Board since HeartBeam, Inc. founding and in June 2021 stepped down from this position but remains a Board member.Mr. Elfrink actively contributes to portfolio companies via board participation, strategic marketing, governance and capital structure. Mr. Elfrink is also the Founder and President of WPE Ventures Digitized Solutions, a security and digitization solutions investment firm. Mr. Elfrink joined Cisco in 1997 and was Cisco's Executive Vice President of Indtry Solutions and Chief Globalization Officer from 2000 to 2006 and 2007 to 2015 respectively, where Mr. Elfrink made and contributed to key strategic and operational decisions of the Company. Widely recognized as Cisco's Corporate Entrepreneur in residence, his global charter was to identify significant technology opportunities. Mr. Elfrink also led an indtry initiative — called the Internet of Things World Forum. Before joining Cisco, Mr. Elfrink held management and senior management positions at Olivetti, Xerox, HP, Digital Equipment Corporation and Philips. Mr. Elfrink earned a Bachelor of Engineering degree from the Institute of Technology in Rotterdam, the Netherlands. - 自我们成立以来，Willem Elfrink一直担任董事会主席，并于2021年6月辞去该职位，但仍是董事会成员。Elfrink先生在将新技术引入市场方面拥有超过40年的经验。Elfrink先生通过董事会参与，战略营销，治理和资本结构积极为投资组合公司做出贡献。Elfrink先生也是WPE Ventures Digitized Solutions（一家安全和数字化解决方案投资公司）的创始人兼总裁。Elfrink先生于1997年加入Cisco，并于2000年至2006年和2007年至2015年分别担任Cisco的行业解决方案执行副总裁和首席全球化官，在此Elfrink先生为公司的关键战略和运营决策做出了贡献。他被广泛认为是思科的常驻企业企业家，他的全球章程是确定重要的技术机会。Elfrink还领导了一个名为物联网世界论坛IOTWF的行业倡议。在加入Cisco之前，Elfrink先生在Olivetti，Xerox，HP，Digital Equipment Corporation和Philips担任管理和高级管理职位。Elfrink先生在荷兰鹿特丹的理工学院获得了工程学士学位。
- Willem Elfrink was Chairman of the Board since HeartBeam, Inc. founding and in June 2021 stepped down from this position but remains a Board member.Mr. Elfrink actively contributes to portfolio companies via board participation, strategic marketing, governance and capital structure. Mr. Elfrink is also the Founder and President of WPE Ventures Digitized Solutions, a security and digitization solutions investment firm. Mr. Elfrink joined Cisco in 1997 and was Cisco's Executive Vice President of Indtry Solutions and Chief Globalization Officer from 2000 to 2006 and 2007 to 2015 respectively, where Mr. Elfrink made and contributed to key strategic and operational decisions of the Company. Widely recognized as Cisco's Corporate Entrepreneur in residence, his global charter was to identify significant technology opportunities. Mr. Elfrink also led an indtry initiative — called the Internet of Things World Forum. Before joining Cisco, Mr. Elfrink held management and senior management positions at Olivetti, Xerox, HP, Digital Equipment Corporation and Philips. Mr. Elfrink earned a Bachelor of Engineering degree from the Institute of Technology in Rotterdam, the Netherlands.
- George A. de Urioste
-
George A. de Urioste，结合了30多年的经验，在高科技行业的高级管理。此前，他曾参与10多家公司，担任多种职务，包括董事会董事、首席运营官和首席财务官。从1992年到1998年，他担任Remedy Corporation Software的首席财务官，从2000年到2003年，他担任Aeroprise，Inc.（软件）的首席执行官，从2004年到2006年，他担任Chordiant Software的首席运营官兼首席财务官，他于2008年担任Marvell Technology，Inc.（半导体公司）的临时首席运营官兼首席财务官。从2014年到2018年，他担任Pluribus Networks，Inc.（软件）的首席财务官。从2019年到2020年，他担任4IQ，Inc.（软件）的首席财务官，目前是Mozilla，Inc.（软件）的临时首席财务官。De Urioste的董事经验包括以下公司的审计委员会主席职位:Rainmaker Systems, Inc.（业务外包），从2003年到2005年，Saba Software, Inc.（软件）从2008年到2010年，GCT，Inc.（半导体），从2009年到2011年，Villa Montalvo（表演艺术中心），从2011年到2013年，Bridgelux，该公司于2011年至2016年（LED照明）和Vendavo，Inc.于2013年至2014年（软件）。他也曾担任Aeroprise，Inc.（软件）的董事会主席（从2000年到2005年）。他目前是Silicon Valley Directors Exchange（董事会教育活动的非营利组织）的董事会董事。他拥有南加州大学的本科学位和加州大学伯克利分校的工商管理硕士学位。De Urioste先生也是加利福尼亚州的注册会计师（不活跃）。
George A. de Urioste Previoly, Mr. de Urioste has been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. Mr. de Urioste was Chief Financial Officer of Remedy Corporation (software) from 1992 to 1998 and led the IPO, Chief Executive Officer of Aeroprise, Inc., from 2000 to 2003 (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software), interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc. (semiconductors) during 2008, Chief Financial Officer for Plurib Networks, Inc. (software) 2014 to 2018, Chief Financial Officer for 4iQ, Inc. (software) 2019 to 2020 and interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste's Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (biness outscing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). Mr. de Urioste was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). Mr. de Urioste is currently a Board Director at Decklar Corporation (supply chain intelligence software), Blaize, Inc (NASDAQ: BZAI), semiconductor company for artificial intelligence processing at network edge, where he is chairman of the audit committee and member of the compensation committee, and Silicon Valley Directors Exchange, (a not for profit for Board education events). Mr. de Urioste has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California. - George A. de Urioste，结合了30多年的经验，在高科技行业的高级管理。此前，他曾参与10多家公司，担任多种职务，包括董事会董事、首席运营官和首席财务官。从1992年到1998年，他担任Remedy Corporation Software的首席财务官，从2000年到2003年，他担任Aeroprise，Inc.（软件）的首席执行官，从2004年到2006年，他担任Chordiant Software的首席运营官兼首席财务官，他于2008年担任Marvell Technology，Inc.（半导体公司）的临时首席运营官兼首席财务官。从2014年到2018年，他担任Pluribus Networks，Inc.（软件）的首席财务官。从2019年到2020年，他担任4IQ，Inc.（软件）的首席财务官，目前是Mozilla，Inc.（软件）的临时首席财务官。De Urioste的董事经验包括以下公司的审计委员会主席职位:Rainmaker Systems, Inc.（业务外包），从2003年到2005年，Saba Software, Inc.（软件）从2008年到2010年，GCT，Inc.（半导体），从2009年到2011年，Villa Montalvo（表演艺术中心），从2011年到2013年，Bridgelux，该公司于2011年至2016年（LED照明）和Vendavo，Inc.于2013年至2014年（软件）。他也曾担任Aeroprise，Inc.（软件）的董事会主席（从2000年到2005年）。他目前是Silicon Valley Directors Exchange（董事会教育活动的非营利组织）的董事会董事。他拥有南加州大学的本科学位和加州大学伯克利分校的工商管理硕士学位。De Urioste先生也是加利福尼亚州的注册会计师（不活跃）。
- George A. de Urioste Previoly, Mr. de Urioste has been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. Mr. de Urioste was Chief Financial Officer of Remedy Corporation (software) from 1992 to 1998 and led the IPO, Chief Executive Officer of Aeroprise, Inc., from 2000 to 2003 (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software), interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc. (semiconductors) during 2008, Chief Financial Officer for Plurib Networks, Inc. (software) 2014 to 2018, Chief Financial Officer for 4iQ, Inc. (software) 2019 to 2020 and interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste's Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (biness outscing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). Mr. de Urioste was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). Mr. de Urioste is currently a Board Director at Decklar Corporation (supply chain intelligence software), Blaize, Inc (NASDAQ: BZAI), semiconductor company for artificial intelligence processing at network edge, where he is chairman of the audit committee and member of the compensation committee, and Silicon Valley Directors Exchange, (a not for profit for Board education events). Mr. de Urioste has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California.
- Mark Strome
-
Mark E. Strome是美利坚合众国公民。Strome先生的主要职业是管理公司的普通合伙人Strome Group，Inc.的创始人和首席执行官。
Mark Strome combines over 40 years of experience in the investment management and securities indtry. Mr. Strome is the Founder, Chief Investment Officer, and Chairman at Strome Investment Management, L.P. and Strome Group, Inc. Under his leadership, Mr. Strome's investment management company has managed private placement hedge fund investments focing on non traditional investments including commodities, currencies, bankruptcy reorganizations, and numero venture capital and private equity investments. Mr. Strome has also been involved in the founding and incubation of numero publicly traded companies and several successful private companies. These include Pulse Biosciences, and iWood Studios, a company that creates original content for film and TV. Mr. Strome has been a member of the Board of Directors of multiple companies over the last three decades. Mr. Strome has served as a Director at Endurance Ventures, National Water and Por, Eco Duro Corporation, NWP Services Corporation and Mobil Satellite Ventures. Mr. Strome served as Member of Advisory Board at Global Analytics, Inc. Mr. Strome earned a Bachelor of Science in Engineering from Old Dominion University and Master in Economics from the University of California at Berkeley. - Mark E. Strome是美利坚合众国公民。Strome先生的主要职业是管理公司的普通合伙人Strome Group，Inc.的创始人和首席执行官。
- Mark Strome combines over 40 years of experience in the investment management and securities indtry. Mr. Strome is the Founder, Chief Investment Officer, and Chairman at Strome Investment Management, L.P. and Strome Group, Inc. Under his leadership, Mr. Strome's investment management company has managed private placement hedge fund investments focing on non traditional investments including commodities, currencies, bankruptcy reorganizations, and numero venture capital and private equity investments. Mr. Strome has also been involved in the founding and incubation of numero publicly traded companies and several successful private companies. These include Pulse Biosciences, and iWood Studios, a company that creates original content for film and TV. Mr. Strome has been a member of the Board of Directors of multiple companies over the last three decades. Mr. Strome has served as a Director at Endurance Ventures, National Water and Por, Eco Duro Corporation, NWP Services Corporation and Mobil Satellite Ventures. Mr. Strome served as Member of Advisory Board at Global Analytics, Inc. Mr. Strome earned a Bachelor of Science in Engineering from Old Dominion University and Master in Economics from the University of California at Berkeley.
- Kenneth Nelson
-
Kenneth Nelson是一位20年的数字健康、医疗设备和远程患者监测执行官和创新者。在过去10年中，Nelson先生为心脏数字健康和远程患者监测市场份额排名前4位的公司中的3家领导了数字健康、可耕地和心脏远程患者监测指数领域颠覆性技术的商业努力，其中包括BioTelemetry担任销售副总裁、iRhythm担任销售和营销副总裁以及Bardy Diagnostics担任首席商务官。最近，他担任领先的心脏数字健康和医疗设备公司Biotronik的Digital Health、诊断和监测主管。Nelson先生目前担任Medtech Advantage Fund的合伙人，该基金与全球最大的医疗技术和数字健康创业加速器Medtech Innovator建立了长期合作关系。此外，他还担任CardiaCare的董事会主席，并且是少数其他颠覆性心脏数字健康和医疗技术初创公司的活跃董事会成员。Nelson先生获得范德比尔特大学经济学文学士学位，毕业于菲利普斯埃克塞特学院。
Kenneth Nelson is a 20 year digital health, medical device, and remote patient monitoring executive and innovator. Over the past 10 years, Mr. Nelson has led commercial efforts for disruptive technologies in the digital health, arables, and cardiac remote patient monitoring indtries for 3 of the top 4 market share players in cardiac digital health and remote patient monitoring including BioTelemetry as VP of Sales, iRhythm as VP of Sales & Marketing, and Bardy Diagnostics as Chief Commercial Officer. Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring for Biotronik, a leading cardiac digital health and medical device company. Mr. Nelson currently serves as partner in the Medtech Advantage Fund, which has an exclive partnership with Medtech Innovator, the largest medtech and digital health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare, and is an active board member in a handful of other disruptive cardiac digital health and medtech startups. Mr. Nelson earned a Bachelor of Arts in Economics from Vanderbilt University and is a graduate of Phillips Exeter Academy. - Kenneth Nelson是一位20年的数字健康、医疗设备和远程患者监测执行官和创新者。在过去10年中，Nelson先生为心脏数字健康和远程患者监测市场份额排名前4位的公司中的3家领导了数字健康、可耕地和心脏远程患者监测指数领域颠覆性技术的商业努力，其中包括BioTelemetry担任销售副总裁、iRhythm担任销售和营销副总裁以及Bardy Diagnostics担任首席商务官。最近，他担任领先的心脏数字健康和医疗设备公司Biotronik的Digital Health、诊断和监测主管。Nelson先生目前担任Medtech Advantage Fund的合伙人，该基金与全球最大的医疗技术和数字健康创业加速器Medtech Innovator建立了长期合作关系。此外，他还担任CardiaCare的董事会主席，并且是少数其他颠覆性心脏数字健康和医疗技术初创公司的活跃董事会成员。Nelson先生获得范德比尔特大学经济学文学士学位，毕业于菲利普斯埃克塞特学院。
- Kenneth Nelson is a 20 year digital health, medical device, and remote patient monitoring executive and innovator. Over the past 10 years, Mr. Nelson has led commercial efforts for disruptive technologies in the digital health, arables, and cardiac remote patient monitoring indtries for 3 of the top 4 market share players in cardiac digital health and remote patient monitoring including BioTelemetry as VP of Sales, iRhythm as VP of Sales & Marketing, and Bardy Diagnostics as Chief Commercial Officer. Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring for Biotronik, a leading cardiac digital health and medical device company. Mr. Nelson currently serves as partner in the Medtech Advantage Fund, which has an exclive partnership with Medtech Innovator, the largest medtech and digital health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare, and is an active board member in a handful of other disruptive cardiac digital health and medtech startups. Mr. Nelson earned a Bachelor of Arts in Economics from Vanderbilt University and is a graduate of Phillips Exeter Academy.
- Robert P. Eno
-
Robert P. Eno被任命为董事会成员，自2025年5月5日起生效。他为包括冠状动脉疾病无创FFRCT诊断、激光白内障手术、扫描激光光凝和血管内近距离治疗在内的多个突破性产品创建了go to market策略。在加入HeartBeam之前，Eno先生是Preview Medical，Inc.的首席执行官，该公司是一家诊断设备公司，在机器学习和专有光信号方面为实体肿瘤癌症创造了一个新的实时、体内组织分类类别。Previoly，他曾担任HeartFlow，Inc.市场营销高级副总裁，领导针对心脏病的个性化、无创检测这一新品类的营销和产品功能的所有方面，包括其初始产品HeartFlow FFRCT。他还曾在OptiMedica（被Abbott收购）、NeoGuide Systems（被Intuitive收购）和Avantec Vascular（被Goodman Co. Ltd收购）担任高级营销和销售领导职务。Eno先生的职业生涯始于Guidant，在那里他在Vascular Intervention BINESS担任了一系列营销和战略规划职务。他拥有斯坦福大学BYES研究生院的MBA学位和斯坦福大学的荣誉和杰出学士学位，在那里他是Phi Beta Kappa。
Robert P. Eno was appointed to the board of directors effective May 5, 2025.He has created go to market strategies for multiple breakthrough products including noninvasive FFRCT diagnostic for coronary artery disease, laser cataract surgery, scanning laser photocoagulation and intravascular brachytherapy. Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, Inc., a diagnostic equipment company creating a new category of real time, in vivo tissue classification for solid tumor cancers ing machine learning and proprietary optical signals. Previoly, he served as Senior Vice President of Marketing for HeartFlow, Inc. leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive) and Avantec Vascular (acquired by Goodman Co. Ltd). Mr. Eno began his career at Guidant, where he held a series of marketing and strategic planning roles in the Vascular Intervention biness. He holds an MBA from the Stanford Graduate School of Biness and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa. - Robert P. Eno被任命为董事会成员，自2025年5月5日起生效。他为包括冠状动脉疾病无创FFRCT诊断、激光白内障手术、扫描激光光凝和血管内近距离治疗在内的多个突破性产品创建了go to market策略。在加入HeartBeam之前，Eno先生是Preview Medical，Inc.的首席执行官，该公司是一家诊断设备公司，在机器学习和专有光信号方面为实体肿瘤癌症创造了一个新的实时、体内组织分类类别。Previoly，他曾担任HeartFlow，Inc.市场营销高级副总裁，领导针对心脏病的个性化、无创检测这一新品类的营销和产品功能的所有方面，包括其初始产品HeartFlow FFRCT。他还曾在OptiMedica（被Abbott收购）、NeoGuide Systems（被Intuitive收购）和Avantec Vascular（被Goodman Co. Ltd收购）担任高级营销和销售领导职务。Eno先生的职业生涯始于Guidant，在那里他在Vascular Intervention BINESS担任了一系列营销和战略规划职务。他拥有斯坦福大学BYES研究生院的MBA学位和斯坦福大学的荣誉和杰出学士学位，在那里他是Phi Beta Kappa。
- Robert P. Eno was appointed to the board of directors effective May 5, 2025.He has created go to market strategies for multiple breakthrough products including noninvasive FFRCT diagnostic for coronary artery disease, laser cataract surgery, scanning laser photocoagulation and intravascular brachytherapy. Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, Inc., a diagnostic equipment company creating a new category of real time, in vivo tissue classification for solid tumor cancers ing machine learning and proprietary optical signals. Previoly, he served as Senior Vice President of Marketing for HeartFlow, Inc. leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive) and Avantec Vascular (acquired by Goodman Co. Ltd). Mr. Eno began his career at Guidant, where he held a series of marketing and strategic planning roles in the Vascular Intervention biness. He holds an MBA from the Stanford Graduate School of Biness and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.
- Michael R. Jaff
-
Michael R. Jaff现任波士顿科学国际有限公司首席医疗官兼外周介入部门临床事务、技术和创新副总裁。Previoly，Dr. Jaff是哈佛医学院的医学教授，曾担任牛顿莱斯利医院的院长。在此之前，Jaff博士是首届Paul和Phyllis Fireman Endod血管医学主席，也是马萨诸塞州总医院Fireman血管中心的医疗主任。Dr.是公认的血管医学各方面专家，是血管超声核心实验室VasCore的创始人。Jaff博士出版了300多篇同行评审的出版物和10本教科书，是血管医学学会的前任主席。Jaff博士获得了迪金森学院的学士学位、柯克斯维尔整骨医学学院的博士学位、哈佛大学Biness School的Biness学位和哈佛医学院的荣誉文学博士学位。
Michael R. Jaff is currently Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Previoly, Dr. Jaff was a professor of medicine at Harvard Medical School and served as President of Newton llesley Hospital. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endod Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachetts General Hospital. Dr. is a recognized expert in all aspects of vascular medicine and is the founder of VasCore, the Vascular Ultrasound Core Laboratory. Dr. Jaff has published over 300 peer revied publications and 10 textbooks and is the Past President of the Society for Vascular Medicine. Dr. Jaff received a B.S. from Dickinson College, a D.O. from Kirksville College of Osteopathic Medicine, a Biness degree from Harvard Biness School and an honorary Doctorate of Arts from Harvard Medical School. - Michael R. Jaff现任波士顿科学国际有限公司首席医疗官兼外周介入部门临床事务、技术和创新副总裁。Previoly，Dr. Jaff是哈佛医学院的医学教授，曾担任牛顿莱斯利医院的院长。在此之前，Jaff博士是首届Paul和Phyllis Fireman Endod血管医学主席，也是马萨诸塞州总医院Fireman血管中心的医疗主任。Dr.是公认的血管医学各方面专家，是血管超声核心实验室VasCore的创始人。Jaff博士出版了300多篇同行评审的出版物和10本教科书，是血管医学学会的前任主席。Jaff博士获得了迪金森学院的学士学位、柯克斯维尔整骨医学学院的博士学位、哈佛大学Biness School的Biness学位和哈佛医学院的荣誉文学博士学位。
- Michael R. Jaff is currently Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation of the Peripheral Interventions division at Boston Scientific Corporation. Previoly, Dr. Jaff was a professor of medicine at Harvard Medical School and served as President of Newton llesley Hospital. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endod Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachetts General Hospital. Dr. is a recognized expert in all aspects of vascular medicine and is the founder of VasCore, the Vascular Ultrasound Core Laboratory. Dr. Jaff has published over 300 peer revied publications and 10 textbooks and is the Past President of the Society for Vascular Medicine. Dr. Jaff received a B.S. from Dickinson College, a D.O. from Kirksville College of Osteopathic Medicine, a Biness degree from Harvard Biness School and an honorary Doctorate of Arts from Harvard Medical School.
- Marga Ortigas Wedekind
-
Marga Ortigas Wedekind，2009年1月，她加入Omnicell并担任副总裁负责市场营销。2009年5月，她被任命为副总裁负责全球营销和产品开发。2012年3月，她被任命为副总裁负责全球营销和产品开发。从2002年2月到2008年10月，她担任Xoft, Inc.（一个医疗设备公司）的高级副总裁负责营销、开发、和临床事务 。她早期担任几个高级市场营销职务，包括从1990年1月到2000年2月，她在Guidant Corporation的血管介入部门任职，负责国际和全球销售和市场营销，最终担任其董事负责市场发展。她持有威尔斯利学院（Wellesley College）的政治经济学学士学位，以及斯坦福大学商学院（Stanford Graduate School of Business ）的工商管理硕士学位。
Marga Ortigas Wedekind Board member, has over 30 years of experience in health technology senior management. Ms. Ortigasdekind has been Chief Commercial Strategy Officer of Fogarty Innovation, a non profit educational incubator for early stage medtech companies since December 2019, Executive Vice President of Marketing and Payer Relations for iRhythm Technologies Inc., a publicly traded digital healthcare company from July 2015 through July 2019, Executive Vice President, Global Marketing and Product Development of Omnicell Inc., a publicly traded developer of automated medication dispensing and analytics systems where she led the Marketing, International and Engineering departments from 2009 to 2015, Senior Vice President, Marketing, Development, and Clinical Affairs at Xoft, Inc, a developer of disruptive technology to deliver radiation therapy with capital equipment and high end disposables from 2002 to December 2008. She started her medtech career at Guidant Vascular, now Abbott Vascular. Ms. Ortigas dekind was on the board of Itamar Medical (NASDAQ: ITMR), which provides digitally enabled systems for sleep apnea management until its sale to Zoll Medical in December 2021, Total Flow Medical, an early stage company developing a mechanism to improve safety during on pump open heart surgery and, the Bay Area Cancer Coalition, a non profit organization that supports those affected by breast or ovarian cancer.Ms Ortigas dekind has an undergraduate degree from llesley College and an MBA from the Stanford Graduate School of Biness. - Marga Ortigas Wedekind，2009年1月，她加入Omnicell并担任副总裁负责市场营销。2009年5月，她被任命为副总裁负责全球营销和产品开发。2012年3月，她被任命为副总裁负责全球营销和产品开发。从2002年2月到2008年10月，她担任Xoft, Inc.（一个医疗设备公司）的高级副总裁负责营销、开发、和临床事务 。她早期担任几个高级市场营销职务，包括从1990年1月到2000年2月，她在Guidant Corporation的血管介入部门任职，负责国际和全球销售和市场营销，最终担任其董事负责市场发展。她持有威尔斯利学院（Wellesley College）的政治经济学学士学位，以及斯坦福大学商学院（Stanford Graduate School of Business ）的工商管理硕士学位。
- Marga Ortigas Wedekind Board member, has over 30 years of experience in health technology senior management. Ms. Ortigasdekind has been Chief Commercial Strategy Officer of Fogarty Innovation, a non profit educational incubator for early stage medtech companies since December 2019, Executive Vice President of Marketing and Payer Relations for iRhythm Technologies Inc., a publicly traded digital healthcare company from July 2015 through July 2019, Executive Vice President, Global Marketing and Product Development of Omnicell Inc., a publicly traded developer of automated medication dispensing and analytics systems where she led the Marketing, International and Engineering departments from 2009 to 2015, Senior Vice President, Marketing, Development, and Clinical Affairs at Xoft, Inc, a developer of disruptive technology to deliver radiation therapy with capital equipment and high end disposables from 2002 to December 2008. She started her medtech career at Guidant Vascular, now Abbott Vascular. Ms. Ortigas dekind was on the board of Itamar Medical (NASDAQ: ITMR), which provides digitally enabled systems for sleep apnea management until its sale to Zoll Medical in December 2021, Total Flow Medical, an early stage company developing a mechanism to improve safety during on pump open heart surgery and, the Bay Area Cancer Coalition, a non profit organization that supports those affected by breast or ovarian cancer.Ms Ortigas dekind has an undergraduate degree from llesley College and an MBA from the Stanford Graduate School of Biness.
高管简历
中英对照 | 中文 | 英文- Richard Ferrari
Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida.- Richard Ferrari，2007年2月起，担任本公司董事。Ferrari先生是De Novo Ventures（一家致力于医疗设备和生物技术的梦百合投资公司）的联合创始人和董事总经理。Ferrari先生还担任斯坦福生物设计新兴企业家论坛（Stanford Biodesign Emergencers Forum）的教员，以及斯坦福库尔特转化医学基金会（Stanford Coulter Foundation for Translational Medicine）的董事会成员。Ferrari从1995年10月到1999年5月联合创立CardioThoracic Systems，Inc.（一家手术医疗技术和设备公司）并担任首席执行官。Ferrari从1990年1月到1995年6月担任Cardiovascular Imaging Systems（超声成像开发商）首席执行官。Ferrari先生拥有Ashland University的B.S.和University of South Florida的M.B.A.。
- Richard Ferrari is a founder, a director and Executive Chairman of the Company. Since 2000, Mr. Ferrari has been and currently is a co founder and Board Member of Denovo Ventures, a $650 million venture firm specializing in Medical Devices and Biotechnology. From January 2019 until April 2021 Mr. Ferrari was employed as Chief Executive Officer and Chairman of the Board of Directors of PQ Bypass which culminated is a successful acquisition by Endologix. Mr. Ferrari has been a board member (Vice Chairman) of ABS Interventional from 2020 to the present; a board member (Executive Chairman) of Heart Beam Inc. from 2020 to the present; and a board member (Chairman of Compensation Committee) of Pulmonx from 2015 to the present. Mr. Ferrari has raised over $1 billion for the companies he has been involved with and been a key member of the various boards M&A teams achieving over $2 billion in Acquisitions. Mr. Ferrari continues to mentor and advise a number of CEO's and start up companies on strategy and building organizations dedicated to delivering excellence. Mr. Ferrari is the creator of Excellence by Choice a series of lectures and presentations to help early stage companies perform at the highest level of execution. Mr. Ferrari received a Bachelor's Degree in Education from Ashland University and an MBA from University of South Florida.
- Branislav Vajdic
Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
Branislav Vajdic founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held vario senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numero patents and publications in the fields of cardiovascular devices as ll as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.- Branislav Vajdic是HeartBeam，Inc.的首席执行官兼创始人，在技术开发和高级管理职位方面拥有30多年的经验。Vajdic博士一直深入参与Heartbeam技术的开发，以符合他对公司的愿景。在加入Heartbeam之前，从2007年到2010年，Vajdic博士担任NewCardio的首席执行官兼创始人，这是一家心血管设备领域的上市公司。从1984年到2007年，他曾任职Intel公司，在那里他曾担任多种高级管理职务。在英特尔，瓦伊迪奇博士是第一个闪存和两个关键发明的设计师，这两个发明使闪存成为一种产品，并领导了负责奔腾1到奔腾4设计的工程团队。瓦伊迪奇博士获得了两项英特尔成就奖，这是对英特尔做出杰出贡献的最高级别的奖项。Vajdic博士是心血管设备以及芯片设计领域的众多专利和出版物的作者。Vajdic博士拥有明尼苏达大学电气工程博士学位。
- Branislav Vajdic founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam's technology to fit his vision for the Company. Prior to HeartBeam from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space, from 1984 to 2007, Dr. Vajdic was at Intel, where he held vario senior management positions. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numero patents and publications in the fields of cardiovascular devices as ll as chip design. Dr. Vajdic holds a PhD degree in Electrical Engineering from the University of Minnesota.
- Robert P. Eno
Robert P. Eno被任命为董事会成员，自2025年5月5日起生效。他为包括冠状动脉疾病无创FFRCT诊断、激光白内障手术、扫描激光光凝和血管内近距离治疗在内的多个突破性产品创建了go to market策略。在加入HeartBeam之前，Eno先生是Preview Medical，Inc.的首席执行官，该公司是一家诊断设备公司，在机器学习和专有光信号方面为实体肿瘤癌症创造了一个新的实时、体内组织分类类别。Previoly，他曾担任HeartFlow，Inc.市场营销高级副总裁，领导针对心脏病的个性化、无创检测这一新品类的营销和产品功能的所有方面，包括其初始产品HeartFlow FFRCT。他还曾在OptiMedica（被Abbott收购）、NeoGuide Systems（被Intuitive收购）和Avantec Vascular（被Goodman Co. Ltd收购）担任高级营销和销售领导职务。Eno先生的职业生涯始于Guidant，在那里他在Vascular Intervention BINESS担任了一系列营销和战略规划职务。他拥有斯坦福大学BYES研究生院的MBA学位和斯坦福大学的荣誉和杰出学士学位，在那里他是Phi Beta Kappa。
Robert P. Eno was appointed to the board of directors effective May 5, 2025.He has created go to market strategies for multiple breakthrough products including noninvasive FFRCT diagnostic for coronary artery disease, laser cataract surgery, scanning laser photocoagulation and intravascular brachytherapy. Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, Inc., a diagnostic equipment company creating a new category of real time, in vivo tissue classification for solid tumor cancers ing machine learning and proprietary optical signals. Previoly, he served as Senior Vice President of Marketing for HeartFlow, Inc. leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive) and Avantec Vascular (acquired by Goodman Co. Ltd). Mr. Eno began his career at Guidant, where he held a series of marketing and strategic planning roles in the Vascular Intervention biness. He holds an MBA from the Stanford Graduate School of Biness and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.- Robert P. Eno被任命为董事会成员，自2025年5月5日起生效。他为包括冠状动脉疾病无创FFRCT诊断、激光白内障手术、扫描激光光凝和血管内近距离治疗在内的多个突破性产品创建了go to market策略。在加入HeartBeam之前，Eno先生是Preview Medical，Inc.的首席执行官，该公司是一家诊断设备公司，在机器学习和专有光信号方面为实体肿瘤癌症创造了一个新的实时、体内组织分类类别。Previoly，他曾担任HeartFlow，Inc.市场营销高级副总裁，领导针对心脏病的个性化、无创检测这一新品类的营销和产品功能的所有方面，包括其初始产品HeartFlow FFRCT。他还曾在OptiMedica（被Abbott收购）、NeoGuide Systems（被Intuitive收购）和Avantec Vascular（被Goodman Co. Ltd收购）担任高级营销和销售领导职务。Eno先生的职业生涯始于Guidant，在那里他在Vascular Intervention BINESS担任了一系列营销和战略规划职务。他拥有斯坦福大学BYES研究生院的MBA学位和斯坦福大学的荣誉和杰出学士学位，在那里他是Phi Beta Kappa。
- Robert P. Eno was appointed to the board of directors effective May 5, 2025.He has created go to market strategies for multiple breakthrough products including noninvasive FFRCT diagnostic for coronary artery disease, laser cataract surgery, scanning laser photocoagulation and intravascular brachytherapy. Before joining HeartBeam, Mr. Eno was Chief Executive Officer of Preview Medical, Inc., a diagnostic equipment company creating a new category of real time, in vivo tissue classification for solid tumor cancers ing machine learning and proprietary optical signals. Previoly, he served as Senior Vice President of Marketing for HeartFlow, Inc. leading all aspects of the marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive) and Avantec Vascular (acquired by Goodman Co. Ltd). Mr. Eno began his career at Guidant, where he held a series of marketing and strategic planning roles in the Vascular Intervention biness. He holds an MBA from the Stanford Graduate School of Biness and a BA, with Honors and Distinction, from Stanford University, where he was Phi Beta Kappa.
- Timothy Cruickshank
Timothy Cruickshank，自2008年起担任ImpediMed的财务主管，并于2019年10月至2024年3月担任首席财务官。ImpediMed是一家医疗技术公司，利用其开创性的生物阻抗谱（BIS）技术设计和制造医疗设备和软件服务，用于多种适应症，包括心力衰竭、蛋白质卡路里营养不良和肿瘤学领域的淋巴水肿。CruickShank先生在ImpediMed任职期间，通过推出SOZO，他带领公司从一家传统的医疗设备公司演变为一家具有高利润率软件即服务（SaaS）商业模式的医疗技术公司Digital Health平台。曾获凯勒管理研究生院工商管理硕士学位和雪城大学会计学学士学位。
Timothy Cruickshank,was a financial executive of ImpediMed since 2008 and served as CFO from October 2019 through March 2024. ImpediMed is a medical technology company that designs and manufactures medical devices and software services employing its pioneering bioimpedance spectroscopy (BIS) technology for multiple indications including heart failure, protein calorie malnutrition, and lymphedema within oncology. During Mr. Cruickshank's time at ImpediMed, he spearheaded the evolution of the company from a traditional medical device company to a medical technology company with a high margin Software-as-a-Service (SaaS) business model, through the launch of the SOZO Digital Health Platform. He received a Master of Business Administration from Keller Graduate School of Management and a Bachelor of Science in Accounting from Syracuse University.- Timothy Cruickshank，自2008年起担任ImpediMed的财务主管，并于2019年10月至2024年3月担任首席财务官。ImpediMed是一家医疗技术公司，利用其开创性的生物阻抗谱（BIS）技术设计和制造医疗设备和软件服务，用于多种适应症，包括心力衰竭、蛋白质卡路里营养不良和肿瘤学领域的淋巴水肿。CruickShank先生在ImpediMed任职期间，通过推出SOZO，他带领公司从一家传统的医疗设备公司演变为一家具有高利润率软件即服务（SaaS）商业模式的医疗技术公司Digital Health平台。曾获凯勒管理研究生院工商管理硕士学位和雪城大学会计学学士学位。
- Timothy Cruickshank,was a financial executive of ImpediMed since 2008 and served as CFO from October 2019 through March 2024. ImpediMed is a medical technology company that designs and manufactures medical devices and software services employing its pioneering bioimpedance spectroscopy (BIS) technology for multiple indications including heart failure, protein calorie malnutrition, and lymphedema within oncology. During Mr. Cruickshank's time at ImpediMed, he spearheaded the evolution of the company from a traditional medical device company to a medical technology company with a high margin Software-as-a-Service (SaaS) business model, through the launch of the SOZO Digital Health Platform. He received a Master of Business Administration from Keller Graduate School of Management and a Bachelor of Science in Accounting from Syracuse University.